RELATED PARTIES

12 Months Ended

Dec. 31, 2019

Related Party Transactions [Abstract]

RELATED PARTIES

RELATED PARTIES

The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the years ended December 31, 2019, 2018 and 2017, the Company recognized net revenues of $35 million, $36 million, and $37 million, respectively, associated with diagnostic information services provided to its equity method investees. As of December 31, 2019 and December 31, 2018, there was $4 million and $3 million of accounts receivable from equity method investees related to such services, respectively. During the year ended December 31, 2019, the Company recognized net revenues of $8 million associated with diagnostic information services provided to a noncontrolling interest partner in a joint venture. As of December 31, 2019, there was $4 million of receivables from the noncontrolling interest partner included in accounts receivable and other assets related to such services.

During the years ended December 31, 2019, 2018 and 2017, the Company recognized income of $15 million, $15 million and $16 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. As of December 31, 2019 and December 31, 2018, there was $1 million and $3 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of December 31, 2019 and December 31, 2018 included $2 million and $1 million, respectively, due to equity method investees.

During the years ended December 31, 2019, 2018 and 2017, the Company received dividends from its equity method investees of $48 million, $74 million, and $35 million, respectively.

During the year ended December 31, 2018, the Company contributed $10 million to an equity method investee to fund its share of an acquisition made by the equity method investee.